Last reviewed · How we verify
travoprost 0.004%
Travoprost 0.004%, marketed by Allergan, is a well-established treatment in the glaucoma market. The drug's key strength lies in its strong patent protection, with the key composition patent expiring in 2028. The primary risk to the drug's market position is the eventual loss of exclusivity post-patent expiry, which could lead to increased competition from generics.
At a glance
| Generic name | travoprost 0.004% |
|---|---|
| Also known as | Travatan® Z, Travatan Z®, TRAVATAN® BAK-free |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG) (PHASE4)
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost (PHASE4)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- travoprost 0.004% CI brief — competitive landscape report
- travoprost 0.004% updates RSS · CI watch RSS
- Allergan portfolio CI